The experiments performed used a process called RNA interference (RNAi) to specifically ‘silence’ the expression of Boris in cancer cells. The results demonstrated that the cancer cells in which the Boris gene was blocked induced their own death, whereas non-cancer cells treated with the agent that blocks Boris were unaffected.
Boris Reznik, chairman of OncoMune, said: “OncoMune has filed several patent applications covering molecular entities capable of inducing RNA interference against Boris. The scientific acceptance of our work supports the possibility of OncoMune expanding its therapeutic pipeline to include siRNA therapeutics.”